Klinikum Dortmund gGmbH
- Address
- lock Available on a paid plan
Diabetic Polyneuropathy Pain
The Neurology department at Klinikum Dortmund gGmbH is evaluating a new add‑on therapy for patients suffering from chronic pain linked to diabetic polyneuropathy. The study is based at Klinikum Dortmund gGmbH. It targets diabetic polyneuropathy related chronic pain. The investigational drug AP707 is being tested for efficacy and tolerability.
- Efficacy assessment
- Safety and tolerability
- Add‑on treatment strategy
These trials fall under the Diseases [C] – Pathological Conditions, Signs and Symptoms therapeutic area.
Traumatic or Post‑Operative Peripheral Neuropathy Pain
Researchers at the Clinic for Neurology are conducting a study to improve pain management after nerve injury. The trial takes place at Klinikum Dortmund gGmbH. It focuses on chronic pain caused by traumatic or post‑operative peripheral neuropathy. The candidate therapy AP707 is evaluated as an add‑on to standard care.
- Evaluation of add‑on efficacy
- Patient‑reported outcome measures
- Assessment of tolerability
This work contributes to the broader Diseases [C] – Pathological Conditions, Signs and Symptoms research portfolio.
Central Neuropathy Pain of Any Genesis
The Neurology clinic is investigating novel options for chronic pain arising from central nervous system damage. The investigation is conducted at Klinikum Dortmund gGmbH. Participants experience central neuropathy pain regardless of its origin. The study tests the efficacy of AP707 as an adjunct therapy.
- Measurement of pain reduction
- Monitoring of adverse events
- Quality‑of‑life evaluation
These efforts are part of the Diseases [C] – Pathological Conditions, Signs and Symptoms therapeutic focus at the site.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Apurano Pharmaceuticals GmbH3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Dortmund gGmbH
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma | Bristol-Myers Squibb Services Unlimited Company | Phase III | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adezunap | 3 | Unknown | 2023-11-02 | 2023-11-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.